MedMen is opting out of a transaction with Pharmacann as it increases its focus on profitability, says CEO Adam Bierman.
When an M&A transaction is flagged for a deeper regulatory review, the buyer and seller may be faced with significant challenges.
The activist fund allegedly failed to comply with premerger notification rules before acquiring stock in DowDuPont two years ago.
The companies allegedly structured a deal so it would not be delayed by U.S. pre-merger notification laws.
ValueAct failed to notify regulators that it purchased stock in Baker Hughes and Halliburton after the two companies proposed a merger, says the DOJ.
Equity grants could trigger financial penalties for executives and directors.
